Eloxx Pharmaceuticals director files initial ownership

Eloxx Pharmaceuticals director Stephen W. Webster has filed an initial ownership report with the SEC.

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Stephen W. Webster has filed an initial ownership report with the SEC. This Form 3 filing identifies him as a director of Eloxx Pharmaceuticals, Inc. and, in the data provided, shows no reportable transactions, holdings, or derivative positions at the time of the filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Eloxx (ELOX) Form 3 filing for Stephen W. Webster show?

The Form 3 shows that Stephen W. Webster is a director of Eloxx Pharmaceuticals, Inc. and, in this filing, reports no transactions, holdings, or derivative positions as of the filing date.

Is Stephen W. Webster an officer or major shareholder of Eloxx (ELOX) in this Form 3?

The filing identifies Stephen W. Webster only as a director. It does not list him as an officer or as a ten percent owner based on the provided structured data.

Does the Eloxx (ELOX) Form 3 include any stock purchases or sales by Stephen W. Webster?

No. The structured transaction data for this Form 3 shows no reported transactions, with all buy, sell, and other transaction counts recorded as zero in the summary.

Are there any derivative securities reported for Stephen W. Webster in the Eloxx (ELOX) Form 3?

No. The derivative summary in the filing is empty, and derivative-related transaction counts are zero, indicating no reportable options, warrants, or similar instruments in this Form 3.

What is the main purpose of this Eloxx (ELOX) Form 3 filing?

This Form 3 serves as an initial statement of beneficial ownership for director Stephen W. Webster, formally identifying his insider status with Eloxx Pharmaceuticals, Inc. without reporting any current transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 07:00 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Webster Stephen W

(Last) (First) (Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON MASSACHUSETTS 02476

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/27/2026

3. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24, Power of Attorney, is attached.

No securities are beneficially owned.

	/s/ Sumit Aggarwal, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)